Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000221888 | SCV000273185 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-11-21 | criteria provided, single submitter | clinical testing | The p.K1903E variant (also known as c.5707A>G), located in coding exon 37 of the ATM gene, results from an A to G substitution at nucleotide position 5707. The lysine at codon 1903 is replaced by glutamic acid, an amino acid with similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV000468754 | SCV000546955 | uncertain significance | Ataxia-telangiectasia syndrome | 2023-11-02 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with glutamic acid, which is acidic and polar, at codon 1903 of the ATM protein (p.Lys1903Glu). This variant is present in population databases (rs765027485, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with ATM-related conditions. ClinVar contains an entry for this variant (Variation ID: 229836). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Sema4, |
RCV000221888 | SCV002529135 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-10-27 | criteria provided, single submitter | curation | |
Gene |
RCV002259323 | SCV002538919 | uncertain significance | not provided | 2023-06-29 | criteria provided, single submitter | clinical testing | Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Fulgent Genetics, |
RCV002485414 | SCV002780984 | uncertain significance | Familial cancer of breast; Ataxia-telangiectasia syndrome | 2022-05-13 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003230456 | SCV003929136 | uncertain significance | not specified | 2023-04-27 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000468754 | SCV002077237 | uncertain significance | Ataxia-telangiectasia syndrome | 2020-10-22 | no assertion criteria provided | clinical testing |